AR035879A1 - Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen - Google Patents
Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienenInfo
- Publication number
- AR035879A1 AR035879A1 ARP020101681A ARP020101681A AR035879A1 AR 035879 A1 AR035879 A1 AR 035879A1 AR P020101681 A ARP020101681 A AR P020101681A AR P020101681 A ARP020101681 A AR P020101681A AR 035879 A1 AR035879 A1 AR 035879A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- halogen
- nitrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Structural Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
Abstract
Derivados de cianoantranilamida de fórmula general (1), en donde A representa el grupo -N(R7)-; W es oxígeno, azufre, dos átomos de hidrógeno o el grupo -N(R8)-; Z es una unión, el grupo -N(R10)- ó =N-, alquilo C1-12 ramificado o no ramificado o el grupo -(CRaRb)m(CRcRd)n(CReRf)o-; m, n y o son 0-3; Ra, Rb, Rc, Rd, Re, Rf, son, independientemente entre sí, hidrógeno, flúor, alquilo C1-4 o el grupo -N(R11)- y/o Ra y/o Rb con Rc y/o Rd o Rc con Re y/o Rf pueden formar una unión, o hasta dos de los radicales Ra-Rf pueden formar un puente, cada uno de ellos con hasta 3 átomos de C hacia R1 o hacia R7; X es alquilo C1-6; R1 es alquilo C1-12 o alquenilo C2-12 ramificado o no ramificado, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, alquiloxi C1-6, aralquiloxi, alquilo C1-6 y/o por el grupo NR12R13, o es cicloalquilo C3-10 o cicloalquenilo C3-10, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, alquiloxi C1-6, alquilo C1-6 y/o por el grupo NR12R13, o es arilo o hetarilo, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, alquiloxi C1-6, aralquiloxi, alquilo C1-6, haloalquilo C1-6, cianoalquilo C1-6 o por el grupo =O, -OR14 ó -R14; Y1 a Y5 son, cada uno, un átomo de nitrógeno o el grupo -CY6; Y6 es ciano, halógeno, alquilo C1-6, alcoxi C1-6, amino o hidroxi, donde el anillo contiene por lo menos un átomo de nitrógeno y el anillo contiene por lo menos un radical ciano; D es un átomo de nitrógeno o el grupo C-R3; E es un átomo de nitrógeno o el grupo C-R4; F es un átomo de nitrógeno o el grupo C-R5; G es un átomo de nitrógeno o el grupo C-R6; donde R3, R4, R5 y R6 son hidrógeno, halógeno o alcoxi C1-6, alquilo C1-6 o carboxialquilo C1-6 no sustituido o en caso dado, mono- o polisustituido por halógeno; R7 es hidrógeno o alquilo C1-6 o forma un puente con Ra-Rf desde Z o hacia R1 con hasta 3 miembros de anillo; R8, R9, R10 y R11 son hidrógeno o alquilo C1-6; R12 y R13 son hidrógeno, alquilo C1-6 o forman un anillo que puede contener otro heteroátomo; R14 es el grupo alquilo C1-15-R15, donde el radical alquilo puede estar interrumpido una o varias veces por oxígeno o el grupo (CH2-CH2-O)u(CH2)v-R15; R15 es arilo, hetarilo, alquilo C1-6, aralquilo, -CH2CN o el grupo NR16R17; R16 y R17 son hidrógeno, alquilo C1-6, acilo C1-6 o forman un anillo que puede contener otro heteroátomo; u y v son 0-5; y sus isómeros, enantiómeros y sales. Estos compuestos son identificados como inhibidores de la tirosinakinasa KDR y FLT, y son particularmente apropiados para el tratamiento de aquellas enfermedades que son originadas o estimuladas por la angiogénesis persistente provocada por el receptor VEGF o un aumento de la permeabilidad vascular. Medicamentos que contienen al menos un compuesto de fórmula (1), y el uso de estos compuestos para preparar un medicamento destinado al tratamiento de psoriasis, sarcoma de Kaposi, restenosis tal como, por ejemplo, la restenosis inducida por stent, endometriosis, mal de Crohn, enfermedad de Hodkin, leucemia, artritis tal como la artritis reumatoide, hemangioma, angiofibroma, enfermedades oculares tal como la retinopatía diabética, el glaucoma neovascular, enfermedade renales tal como la glomerulonefritis, nefropatía diabética, nefroesclerosis maligna, síndromes microangiopáticos trómbicos, rechazos de transplantes y glomerulopatía, enfermedades fibróticas como cirrosis hepática, enfermedades proliferativas de celulas masangiales, ateroesclerosis, lesiones del tejido nervioso, inhibición de la reoclusión de vasos después de cateterismo con globo dilatable, a la colocación de prótesis vasculares o de dispositivos mecánicos para mantener abiertos los vasos como, por ejemplo, stents, a actuar como inmunosupresores y a favorecer la curación de heridas sin dejar cicatriz, y a los casos de léntigo senil y dermatitis de contacto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2001123587 DE10123587B4 (de) | 2001-05-08 | 2001-05-08 | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE2001125295 DE10125295A1 (de) | 2001-05-15 | 2001-05-15 | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035879A1 true AR035879A1 (es) | 2004-07-21 |
Family
ID=26009296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101681A AR035879A1 (es) | 2001-05-08 | 2002-05-08 | Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen |
Country Status (13)
Country | Link |
---|---|
US (1) | US7429592B2 (es) |
EP (1) | EP1387838B1 (es) |
JP (1) | JP4343681B2 (es) |
AR (1) | AR035879A1 (es) |
AT (1) | ATE323694T1 (es) |
CY (1) | CY1105140T1 (es) |
DE (1) | DE50206476D1 (es) |
DK (1) | DK1387838T3 (es) |
ES (1) | ES2261693T3 (es) |
PE (1) | PE20030037A1 (es) |
PT (1) | PT1387838E (es) |
TW (1) | TWI251593B (es) |
WO (1) | WO2003000678A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20040254185A1 (en) * | 2001-05-08 | 2004-12-16 | Alexander Ernst | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
WO2009143584A1 (en) * | 2008-05-30 | 2009-12-03 | Vegenics Limited | Treatment of pulmonary edema |
DK2346827T3 (da) | 2008-08-27 | 2014-02-03 | Leo Pharma As | Pyridinderivater som VEGFR-2 receptor og proteintyrosinkinasehæmmere |
EP2957283B1 (de) | 2014-06-19 | 2022-12-21 | Symrise AG | Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung |
WO2022111793A1 (en) | 2020-11-24 | 2022-06-02 | Symrise Ag | Medicament for accelerated wound healing |
CN112675173B (zh) * | 2020-12-25 | 2022-04-05 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
WO2022161593A1 (en) | 2021-01-26 | 2022-08-04 | Symrise Ag | Medicament for accelerated wound healing |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026260A1 (en) | 1993-05-14 | 1994-11-24 | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 46 Jabotinsky Street | METHODS AND COMPOUNDS FOR INHIBITING CELL PROLIFERATIVE DISORDERS CHARACTERIZED BY ABNORMAL abl ACTIVITY |
EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
DE19910396C2 (de) | 1999-03-03 | 2001-12-13 | Schering Ag | Anthranilsäureamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
-
2002
- 2002-05-03 ES ES02748691T patent/ES2261693T3/es not_active Expired - Lifetime
- 2002-05-03 AT AT02748691T patent/ATE323694T1/de not_active IP Right Cessation
- 2002-05-03 EP EP02748691A patent/EP1387838B1/de not_active Expired - Lifetime
- 2002-05-03 WO PCT/EP2002/004921 patent/WO2003000678A1/de active IP Right Grant
- 2002-05-03 US US10/476,761 patent/US7429592B2/en not_active Expired - Fee Related
- 2002-05-03 PT PT02748691T patent/PT1387838E/pt unknown
- 2002-05-03 JP JP2003507082A patent/JP4343681B2/ja not_active Expired - Fee Related
- 2002-05-03 DK DK02748691T patent/DK1387838T3/da active
- 2002-05-03 DE DE50206476T patent/DE50206476D1/de not_active Expired - Fee Related
- 2002-05-08 TW TW091109572A patent/TWI251593B/zh not_active IP Right Cessation
- 2002-05-08 PE PE2002000386A patent/PE20030037A1/es not_active Application Discontinuation
- 2002-05-08 AR ARP020101681A patent/AR035879A1/es unknown
-
2006
- 2006-07-18 CY CY20061100997T patent/CY1105140T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003000678A1 (de) | 2003-01-03 |
US7429592B2 (en) | 2008-09-30 |
JP4343681B2 (ja) | 2009-10-14 |
DE50206476D1 (de) | 2006-05-24 |
EP1387838A1 (de) | 2004-02-11 |
PE20030037A1 (es) | 2003-02-05 |
DK1387838T3 (da) | 2006-08-14 |
PT1387838E (pt) | 2006-08-31 |
EP1387838B1 (de) | 2006-04-19 |
TWI251593B (en) | 2006-03-21 |
ES2261693T3 (es) | 2006-11-16 |
JP2004532281A (ja) | 2004-10-21 |
CY1105140T1 (el) | 2010-03-03 |
ATE323694T1 (de) | 2006-05-15 |
US20040266770A1 (en) | 2004-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035879A1 (es) | Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
AR035877A1 (es) | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
CA2787121C (en) | Aminopyridine derivatives as anti-malarial agents | |
MY141597A (en) | 2,4-disubstituted thiazolyl derivatives | |
AR054127A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
ZA200603474B (en) | Alkoxy substituted imidazoquinolines | |
RU2017138972A (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
NO20023218D0 (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
EA200800815A1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
ATE312826T1 (de) | 4,5-disubstituierte 2-aminopyrimidine | |
AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
MY140039A (en) | Pyrido-(2,1-a)-isoquinoline derivatives as dpp-iv inhibitors | |
CO5580770A2 (es) | Compuestos de quinolina terapeuticos con propiedades antagonistas de 5-ht | |
AR049696A1 (es) | Derivados de indol | |
EA023998B1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
PE20040189A1 (es) | Pirimidina y piridina biciclicos como inhibidores de p38 quinasa | |
RU2010154425A (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
ES2394324T3 (es) | Piridinureas de nicotinamida como inhibidores de la cinasa del receptor del factor de crecimiento endotelial vascular (VEGF) | |
BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |